Creative Medical Technology Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Creative Medical Technology Holdings, Inc. on August 12, 2021, reporting events occurring on August 9, 2021. The filing details the entry into a material definitive agreement involving the sale of debt securities and warrants to institutional investors.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company sold 15% Original Issue Discount Senior Notes with an aggregate principal amount of $4,456,176.
- Proceeds: The aggregate purchase price received was $3,787,750.
- Interest Terms: The Notes do not bear interest unless an event of default occurs.
- Maturity: The Notes mature on February 11, 2022, subject to earlier redemption with proceeds from future securities offerings.
- Warrant Issuance: The Company issued five-year warrants to purchase an aggregate of 157,184,354 shares of common stock at an exercise price of $0.02835 per share.
- Placement Agent Fees: A fee of $312,750 was paid to Roth Capital Partners, along with a warrant to purchase 10,094,408 shares.
Material Changes
The filing reports a significant increase in short-term debt obligations and potential equity dilution through the issuance of warrants. The transaction was executed under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). The filing text does not provide comparative financial data (revenue, profit, cash flow) for the prior period as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Redemption Obligation: The Company is required to redeem the Notes prior to maturity using net proceeds from any future offering of its securities.
- Dilution Risk: The issuance of over 167 million warrants (including agent warrants) at a low exercise price presents significant potential dilution to existing shareholders.
- Covenants: The Notes are subject to customary covenants and events of default.
Investor Verification Checklist
- Verify the Company's ability to raise future capital to redeem the Notes prior to the February 11, 2022 maturity date.
- Review the full terms of the Securities Purchase Agreement (Exhibit 10.1) for specific default triggers and covenants.
- Assess the impact of the 167,278,762 total warrants issued on the Company's fully diluted share count.
- Confirm the Company's current liquidity position to ensure it can meet operational needs alongside the new debt obligation.